Patent Settlements Stir Supreme Court Interest During Slow Term For Pharma Cases
This article was originally published in The Tan Sheet
High court seeks Solicitor General's view on whether patent settlements blocking authorized generics are anticompetitive; court denies GSK petition challenging payer claims in Avandia litigation.
You may also be interested in...
In addition to settling with Endo, FTC refiles charges against Watson (now Teva), Allergan and Impax involving Lidoderm and Opana ER patent litigation settlements.
GlaxoSmithKline petitions court to review third party payers' RICO claims in Avandia litigation; PhRMA cites 'growing torrent' of such suits against drug makers.
US Supreme Court denies J&J petition seeking review of South Carolina’s $124m judgment related to Risperdal marketing, giving state unfair trade practice laws a boost.